Research Article
Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease
Table 1
Baseline characteristics of the studied patients.
| Variables | (, %) |
| Age (years) | | Sex: (%) | | Male | 56 (56%) | Female | 44 (44%) | Presence of cirrhosis: (%) | | (i) Noncirrhotic | 43 (43%) | (ii) Cirrhotic: | 57 (57%) | Child A | 50 (88%) | Child B | 7 (12%) | Portal vein diameter (mm) | | Spleen size (cm) | | Stage of hepatic fibrosis: (%) | | F0 | 6 | F1 | 5 | F2 | 12 | F3 | 6 | F4 | 71 | Mild to moderate fibrosis (F0, F1, and F2) | 23 (23%) | Advanced fibrosis and cirrhosis (F3 and F4) | 77 (77%) | PCR (IU/ml) | | Platelet count (×103/mL) | | WBCs (×103/mL) | | Hemoglobin (g/dL) | | Total bilirubin (mg/dL) | | Albumin (g/dL) | | ALT(IU/L) | | AST (IU/L) | | Treatment type: (%) | | Dual | 29 (29%) | Triple | 71 (71%) |
|
|
SD: standard deviation; : number; PCR: polymerase chain reaction; WBCs: white blood cells; ALT: alanine aminotransferase; AST: aspartate aminotransferase. |